Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease

Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01995-17. doi: 10.1128/AAC.01995-17. Print 2018 Feb.

Abstract

The pharmacodynamic profile of azithromycin against persistent strains of nontypeable Haemophilus influenzae (NTHi) from chronic obstructive pulmonary disease (COPD) patients was characterized. Azithromycin displayed differential concentration-dependent activities (R2 ≥ 0.988); the pharmacodynamic response was attenuated when we compared the "first" and "last" strains of NTHi that persisted in the airways of the same patient for 819 days (the 50% effective concentration [EC50] increased more than 50 times [0.0821 mg/liter versus 4.23 mg/liter]). In the hollow-fiber infection model, NTHi viability was maintained throughout simulated azithromycin (Zithromax) Z-Pak regimens over 10 days.

Keywords: azithromycin; macrolide-lincosamide-streptogramin B; nontypeable H. influenzae.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / therapeutic use*
  • Haemophilus Infections / drug therapy*
  • Haemophilus Infections / microbiology
  • Haemophilus influenzae / drug effects*
  • Humans
  • Pulmonary Disease, Chronic Obstructive / microbiology*
  • Respiratory System / microbiology

Substances

  • Anti-Bacterial Agents
  • Azithromycin